These limitations suggest that future research should adopt longer follow-up periods, larger sample sizes, designs with blinding or placebo control, and more comprehensive renal health indicators to more comprehensively and accurately evaluate the renal protective effect of SGLT2 inhibitors in type 2 diabetes patients. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.